EUVIMEDEUVIMED entdecken
Crossref

Efficacy and immunogenicity of AS04‐HPV ‐16/18 vaccine in females with existing cervical HR‐HPV infection at first vaccination: A pooled analysis of four large clinical trials worldwide

Tian-Meng Wen iD, Xiao-Qian Xu iD, Xue-Lian Zhao iD, Cheng-Hao Pan, Yu-Shu Feng, Ting-Ting You, Meng Gao, Shang-Ying Hu iD, Fang-Hui Zhao iD

International Journal of Cancer · 2024

DOI: 10.1002/ijc.34882 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Tian-Meng Wen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sc…. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Papillomavirus Infections, Papillomavirus Vaccines, Uterine Cervical Dysplasia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: National Natural Science Foundation of China, China Medical Board Open Competition Program (CMB-OC), Chinese Academy of Medical Sciences Initiative for Innovative Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Females with existing high‐risk HPV (HR‐HPV) infections remain at risk of subsequent multiple or recurrent infections, on which benefit from HPV vaccines was under‐reported. We pooled individual‐level data from four large‐scale, RCTs of AS04‐HPV‐16/18 vaccine to evaluate efficacy and immunogenicity in females DNA‐positive to any HR‐HPV types at first vaccination. Females receiving the AS04‐HPV‐16/18 vaccine in the original RCTs constituted the vaccine group in the present study, while those unvaccinated served as the control group. Vaccine efficacy (VE) against new infections and associated cervical intraepithelial neoplasia (CIN) 2+ in females DNA‐negative to the considered HR‐HPV type but positive to any other HR‐HPV types, VE against reinfections in females DNA‐positive to the considered HR‐HPV type but cleared naturally during later follow‐up, and levels of anti‐HPV‐16/18 IgG were assessed. Our final analyses included 5137 females (vaccine group = 2532, control group = 2605). The median follow‐up time was 47.88 months (IQR: 45.72‐50.04). For the prevention of precancerous lesions related to the non‐infected HR‐HPV types at baseline, VE against HPV‐16/18 related CIN 2+ was 82.70% (95% CI: 63.70‐93.00%). For the prevention of reinfections related to the infected HR‐HPV types following natural clearance, VE against HPV‐16/18 12MPI was non‐significant ( p > .05), albeit robust immunity persisted for at least 48 months. Females with existing HR‐HPV infections at first vaccination still benefit from vaccination in preventing precancers related to the non‐infected types at baseline. VE against reinfections related to the infected types following natural clearance remains to be further investigated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsPapillomavirus InfectionsPapillomavirus VaccinesUterine Cervical DysplasiaFemaleHumansHuman papillomavirus 16ReinfectionHuman papillomavirus 18VaccinationDNA

Stichwörter der Autor:innen

clinical trialefficacyhuman papillomavirusimmunogenicityvaccines

Substanzen

Papillomavirus VaccinesDNA

Autor:innen und Institutionen

  • Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Clinical Epidemiology and EBM Unit, National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China.

ORCID-Profile: Tian-Meng Wen, Xiao-Qian Xu, Xue-Lian Zhao, Shang-Ying Hu, Fang-Hui Zhao

Förderung

  • National Natural Science Foundation of China
  • China Medical Board Open Competition Program (CMB-OC)
  • Chinese Academy of Medical Sciences Initiative for Innovative Medicine
  • GlaxoSmithKline (GSK) Biologicals SA
  • GlaxoSmithKline Biologicals

Zitieren

APA

Wen, T. M., Xu, X. Q., Zhao, X. L., Pan, C. H., Feng, Y. S., You, T. T., Gao, M., Hu, S. Y., & Zhao, F. H. (2024). Efficacy and immunogenicity of AS04‐HPV ‐16/18 vaccine in females with existing cervical HR‐HPV infection at first vaccination: A pooled analysis of four large clinical trials worldwide. International Journal of Cancer. https://doi.org/10.1002/ijc.34882

Vancouver

Wen TM, Xu XQ, Zhao XL, Pan CH, Feng YS, You TT, et al. Efficacy and immunogenicity of AS04‐HPV ‐16/18 vaccine in females with existing cervical HR‐HPV infection at first vaccination: A pooled analysis of four large clinical trials worldwide. International Journal of Cancer. 2024. doi:10.1002/ijc.34882

BibTeX
@article{Wen2024,
  author = {Wen, Tian-Meng and Xu, Xiao-Qian and Zhao, Xue-Lian and Pan, Cheng-Hao and Feng, Yu-Shu and You, Ting-Ting and Gao, Meng and Hu, Shang-Ying and Zhao, Fang-Hui},
  title = {Efficacy and immunogenicity of AS04‐HPV ‐16/18 vaccine in females with existing cervical HR‐HPV infection at first vaccination: A pooled analysis of four large clinical trials worldwide},
  journal = {International Journal of Cancer},
  year = {2024},
  doi = {10.1002/ijc.34882}
}
Kostenlos starten →